Pancreatic Cancer
Protocol # M25-288 Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288
- Details
ClinicalTrials.gov ID:
NCT07490301
Diagnosis Type:
NA
USOR Number:
- Address
,
P: